EP 1307183 A2 20030507 - TREATMENT OF THE INSULIN RESISTANCE SYNDROME WITH SELECTIVE CGMP PDE5 INHIBITORS
Title (en)
TREATMENT OF THE INSULIN RESISTANCE SYNDROME WITH SELECTIVE CGMP PDE5 INHIBITORS
Title (de)
BEHANDLUNG DES INSULINRESISTENZSYNDROMS MIT SELEKTIVEN CGMP PDE5 HEMMERN
Title (fr)
TRAITEMENT DU SYNDROME DE LA RESISTANCE A L'INSULINE PAR DES INHIBITEURS SELECTIFS DU CGMP PDE5
Publication
Application
Priority
- GB 0030649 A 20001215
- GB 0106465 A 20010315
- GB 0106468 A 20010315
- GB 0117134 A 20010713
- IB 0101428 W 20010806
- US 22492800 P 20000811
- US 26608301 P 20010202
Abstract (en)
[origin: WO0213798A2] Use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome wherein the insulin resistance syndrome means the concomitant existence in a subject of two or more of: dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity wherein said use can occur alone or in combination with other agents to treat the insulin resistance syndrome or individual aspects of the insulin resistance syndrome.
IPC 1-7
A61K 31/00; A61K 31/505; A61K 31/5355; A61K 31/535; A61K 31/4985; A61K 31/495; A61K 31/53; A61K 38/28; A61K 45/06; A61P 3/04; A61P 3/06; A61P 3/08; A61P 3/10; A61P 9/12; A61P 9/10; A61P 7/04
IPC 8 full level
A61K 45/00 (2006.01); A61K 31/00 (2006.01); A61K 31/4985 (2006.01); A61K 31/505 (2006.01); A61K 31/519 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); A61K 31/64 (2006.01); A61K 38/28 (2006.01); A61K 45/06 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/08 (2006.01); A61P 3/10 (2006.01); A61P 5/50 (2006.01); A61P 7/02 (2006.01); A61P 7/04 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 19/06 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP KR)
A61K 31/00 (2013.01 - EP); A61K 31/4985 (2013.01 - EP); A61K 31/505 (2013.01 - EP KR); A61K 31/519 (2013.01 - EP); A61K 31/53 (2013.01 - EP); A61K 31/5377 (2013.01 - EP); A61K 31/64 (2013.01 - EP); A61K 38/28 (2013.01 - EP); A61K 45/06 (2013.01 - EP); A61P 3/00 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 3/06 (2017.12 - EP); A61P 3/08 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 5/50 (2017.12 - EP); A61P 7/02 (2017.12 - EP); A61P 7/04 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 9/12 (2017.12 - EP); A61P 19/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
C-Set (source: EP)
Citation (search report)
See references of WO 0213798A2
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0213798 A2 20020221; WO 0213798 A3 20030123; AU 7660701 A 20020225; CA 2419033 A1 20020221; CN 1446084 A 20031001; EP 1307183 A2 20030507; HU P0300725 A2 20031128; HU P0300725 A3 20051128; IL 154158 A0 20030731; JP 2004506009 A 20040226; KR 20030023747 A 20030319
DOCDB simple family (application)
IB 0101428 W 20010806; AU 7660701 A 20010806; CA 2419033 A 20010806; CN 01814039 A 20010806; EP 01954266 A 20010806; HU P0300725 A 20010806; IL 15415801 A 20010806; JP 2002518944 A 20010806; KR 20037001961 A 20030210